|
1.
|
|
28 p, 884.5 KB |
Cabozantinib for the treatment of solid tumors : a systematic review
/
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Porta, Camillo (Interdisciplinary Department of Medicine. University of Bari "Aldo Moro) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Apolo, Andrea B. (Center for Cancer Research. National Cancer Institute. National Institutes of Health) ;
Viteri, Santiago (UOMI Cancer Center. Clínica Mi Tres Torres) ;
Rodriguez-Antona, Cristina (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Martin, Lidia (Ipsen Pharma) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre. Servicio de Oncología Médica)
Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. [...]
2022 -  10.1177/17588359221107112
Therapeutic Advances in Medical Oncology, Vol. 14 (2022)
|
|
|
2.
|
|
37 p, 420.1 KB |
Cabozantinib combination therapy for the treatment of solid tumors : a systematic review
/
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Apolo, Andrea B. (Center for Cancer Research. National Cancer Institute. National Institutes of Health) ;
Porta, Camillo (Interdisciplinary Department of Medicine. University of Bari 'Aldo Moro') ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell) ;
Rodriguez-Antona, Cristina (Centro Nacional de Investigaciones Oncológicas) ;
Martin, Lidia (Ipsen Pharma) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau)
Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a systematic review of cabozantinib combination therapy for the treatment of solid tumors in adults. [...]
2022 - 10.1177/17588359221108691
Therapeutic Advances in Medical Oncology, Vol. 14 (2022)
|
|
|
3.
|
|
12 p, 976.6 KB |
SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)
/
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Gómez, M.A. (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Guillot, M. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Pericay, C. (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Safont, M.J. (Consorcio Hospital General Universitario de Valencia. Universidad de Valencia. CIBERONC) ;
Tarazona, N. (Centro de Investigación Biomédica en Red de Cáncer) ;
Vera, R. (DHospital Universitario de Navarra; Navarrabiomed. IDISNA) ;
Vidal, J. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Sastre Valera, Javier (Hospital Universitario Clínico San Carlos (Madrid))
The management of localized rectal cancer requires a multidisciplinary approach to optimize outcomes, reduce morbidity and prevent under or overtreatments. While early stages may obtain benefit of local resections without any additional therapies, locally advanced rectal cancer becomes a challenge defining the better sequential strategy of surgery, radiotherapy and chemotherapy. [...]
2022 - 10.1007/s12094-022-02816-9
Clinical & Translational Oncology, Vol. 24 Núm. 4 (april 2022) , p. 646-657
|
|
|
4.
|
|
16 p, 3.2 MB |
Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT
/
Molla, Meritxell (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Fernandez-Plana, Julen (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Albiol, Santiago (Hospital Clínic i Provincial de Barcelona) ;
Fondevila, Constantino (Hospital Clínic i Provincial de Barcelona) ;
Vollmer, Ivan (Hospital Clínic i Provincial de Barcelona) ;
Cases, Carla (Hospital Clínic i Provincial de Barcelona) ;
García-Criado, A. (Hospital Clínic i Provincial de Barcelona) ;
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Conill, Carles (Hospital Clínic i Provincial de Barcelona) ;
Fundora, Yliam (Hospital Clínic i Provincial de Barcelona) ;
Fernández-Martos, Carlos (Instituto Valenciano Oncologia) ;
Pineda, Estela (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
The prognosis for oligometastatic colorectal cancer has improved in recent years, mostly because of recent advances in new techniques and approaches to the treatment of oligometastases, including new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy (SBRT). [...]
2021 - 10.3390/jcm10102131
Journal of clinical medicine, Vol. 10 (may 2021)
|
|
|
5.
|
|
9 p, 1.6 MB |
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab
/
Trilla-Fuertes, Lucía (Biomedica Molecular Medicine (Madrid)) ;
Gámez-Pozo, Angelo (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
García-Carbonero, Rocío (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
G-Pastrián, Laura (Hospital Universitario La Paz (Madrid)) ;
Mendiola, Marta (Centro de Investigación Biomédica en Red de Cáncer) ;
Peña, Cristina (Hospital Universitario La Paz (Madrid)) ;
López-Vacas, Rocío (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco) ;
Llorens, Carlos (Biotechvana SL (Madrid)) ;
Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ;
Conill, Carles (Hospital Clínic i Provincial de Barcelona) ;
Heredia Soto, Victoria (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Campos-Barros, Ángel (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Fresno Vara, Juan Ángel (Centro de Investigación Biomédica en Red de Cáncer) ;
Feliu, Jaime (Universidad Autónoma de Madrid) ;
Universitat Autònoma de Barcelona
Squamous cell carcinoma is the most frequent histologic type of anal carcinoma. The standard of care since the 1970s has been a combination of 5-fluorouracil, mitomycin C, and radiotherapy. This treatment is very effective in T1/T2 tumors (achieving complete regression in 80-90% of tumors). [...]
2021 - 10.1038/s41598-021-86966-w
Scientific reports, Vol. 11 (april 2021)
|
|
|
6.
|
|
9 p, 1.7 MB |
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
/
Sclafani, Francesco (The Royal Marsden NHS Foundation Trust) ;
Chau, Ian (The Royal Marsden NHS Foundation Trust) ;
Cunningham, David (The Royal Marsden NHS Foundation Trust) ;
Hahne, Jens Claus (The Institute of Cancer Research) ;
Vlachogiannis, George (The Institute of Cancer Research) ;
Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust) ;
Lampis, Andrea (The Institute of Cancer Research) ;
Braconi, Chiara (The Institute of Cancer Research) ;
Kalaitzaki, Eleftheria (The Royal Marsden NHS Foundation Trust) ;
De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust) ;
Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust) ;
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Glimelius, Bengt (University of Uppsala) ;
Tarazona, Noelia (Universitat de València) ;
Begum, Ruwaida (The Royal Marsden NHS Foundation Trust) ;
Lote, Hazel (The Institute of Cancer Research) ;
Hulkki Wilson, Sanna (The Royal Marsden NHS Foundation Trust) ;
Mentrasti, Giulia (The Institute of Cancer Research) ;
Brown, Gina (The Royal Marsden NHS Foundation Trust) ;
Tait, Diana (The Royal Marsden NHS Foundation Trust) ;
Oates, Jacqueline (The Royal Marsden NHS Foundation Trust) ;
Valeri, Nicola (The Institute of Cancer Research) ;
Universitat Autònoma de Barcelona
There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. [...]
2018 - 10.1038/s41598-018-19212-5
Scientific reports, Vol. 8 (january 2018)
|
|
|
7.
|
|
9 p, 801.8 KB |
PD-1 Blockade in Anaplastic Thyroid Carcinoma
/
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Wirth, Lori J. (Harvard Medical School) ;
Ernst, Thomas (Universitätsklinikum Jena) ;
Ponce Aix, Santiago (Hospital Universitario 12 de Octubre (Madrid)) ;
Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ;
Ramlau, Rodryg (Poznań University of Medical Sciences) ;
Butler, Marcus O. (Princess Margaret Cancer Centre) ;
Delord, Jean-Pierre (IUCT Oncopole) ;
Gelderblom, Hans J (Leiden University Medical Center) ;
Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G. Pascale) ;
Fasolo, Angelica (San Raffaele Hospital) ;
Führer, Dagmar (University Hospital Essen (Alemanya)) ;
Hütter-Krönke, Marie Luise (University Hospital of Ulm (Alemanya)) ;
Forde, Patrick M. (Sidney Kimmel Comprehensive Cancer Center) ;
Wrona, Anna (Uniwersyteckie Centrum Kliniczne) ;
Santoro, Armando (IRCCS Humanitas University) ;
Sadow, Peter M. (Harvard Medical School) ;
Szpakowski, Sebastian (Novartis Institutes for BioMedical Research) ;
Wu, Hongqian (Novartis Pharmaceuticals) ;
Bostel, Geraldine (Novartis Institutes for BioMedical Research) ;
Faris, Jason (Novartis Institutes for BioMedical Research) ;
Cameron, Scott (Novartis Institutes for BioMedical Research) ;
Varga, Andreea (Gustave Roussy Cancer Campus) ;
Taylor, Matthew (Oregon Health & Science University) ;
Universitat Autònoma de Barcelona
Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with BRAF -wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1) receptor. [...]
2020 - 10.1200/JCO.19.02727
Journal of Clinical Oncology, Vol. 38 Núm. 23 (may 2020) , p. 2620-2627
|
|
|
8.
|
|
13 p, 11.2 MB |
Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor - an update on neuroendocrine neoplasm's treatment : A case report
/
Mirallas, Oriol (Vall d'Hebron Institut d'Oncologia) ;
Saoudi, Nadia (Vall d'Hebron Institut d'Oncologia) ;
Gomez-Puerto, Diego (Vall d'Hebron Institut d'Oncologia) ;
Riveiro Barciela, Mar (Hospital Universitari Vall d'Hebron) ;
Merino, Xavier (Hospital Universitari Vall d'Hebron) ;
Auger, Cristina (Hospital Universitari Vall d'Hebron) ;
Landolfi, Stefania (Hospital Universitari Vall d'Hebron) ;
Blanco, Laia (Hospital Universitari Vall d'Hebron) ;
Garcia-Burillo, Amparo (Hospital Universitari Vall d'Hebron) ;
Molero, Xavier (Hospital Universitari Vall d'Hebron) ;
Salcedo, Maria-Teresa (Hospital Universitari Vall d'Hebron) ;
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Metastatic small bowel low-grade neuroendocrine tumors (NETs) have a good prognosis. Surgery is the only curative treatment; however, this may induce advanced liver disease, particularly in long-term survivor patients. [...]
2021 - 10.4254/wjh.v13.i5.611
World Journal of Hepatology, Vol. 13 (may 2021) , p. 611-619
|
|
|
9.
|
|
8 p, 1.4 MB |
Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma
/
Trilla-Fuertes, Lucía (Biomedica Molecular Medicine (Madrid)) ;
Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ;
Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
G-Pastrián, Laura (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Mendiola, Marta (Centro de Investigación Biomédica en Red de Cáncer) ;
Peña, Cristina (Hospital Universitario La Paz (Madrid)) ;
López-Vacas, Rocío (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Prado-Vázquez, Guillermo (Biomedica Molecular Medicine (Madrid)) ;
López-Camacho, Elena (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Zapater-Moros, Andrea (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Heredia Soto, Victoria (Hospital Universitario La Paz (Madrid)) ;
Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Conill, Carles (Hospital Clínic i Provincial de Barcelona) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Heath, Karen E. (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ;
Llorens, Carlos (Biotechvana SL, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ;
Campos-Barros, Ángel (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Gámez-Pozo, Angelo (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Feliu, Jaime (Universidad Autónoma de Madrid) ;
Vara, Juan Ángel Fresno (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Anal squamous cell carcinoma (ASCC) is a rare neoplasm. Chemoradiotherapy is the standard of care, with no therapeutic advances achieved over the past three decades. Thus, a deeper molecular characterization of this disease is still necessary. [...]
2020 - 10.1016/j.tranon.2020.100778
Translational Oncology, Vol. 13 (may 2020)
|
|
|
10.
|
|
8 p, 518.2 KB |
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib : comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
/
Solis-Hernandez, Mª Pilar (Hospital Universitario Central de Asturias) ;
Fernandez del Valle, Ana (Hospital Universitario Central de Asturias) ;
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Custodio, Ana (Hospital Universitario La Paz (Madrid)) ;
Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ;
Nuñez-Valdovino, Bárbara (Hospital Clinico Universidad de Chile (Santiago de Xile, Xile)) ;
Sanchez Canovas, Manuel (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Matos, Ignacio (Hospital Universitari Vall d'Hebron) ;
Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ;
Lopez, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Viudez, Antonio (Complejo Hospitalario de Navarra) ;
Izquierdo, Marta (Hospital Universitario Central de Asturias) ;
Calvo-Temprano, David (Hospital Universitario Central de Asturias) ;
Grande, Enrique (MD Anderson Cancer Center) ;
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ;
Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias) ;
Universitat Autònoma de Barcelona ;
Vall d'Hebron Institut d'Oncologia
The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. [...]
2019 - 10.1038/s41416-019-0558-7
British Journal of Cancer, Vol. 121 (september 2019) , p. 537-544
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
